MYCOLab Ai Logo - gold and army green

Galacto-Oligosaccharides Exert Bifidogenic Effects at Capsule-Compatible Ultra-Low Doses

Summary

This study tested whether tiny doses of a prebiotic called galacto-oligosaccharides (GOS) could be effective when taken in capsule form instead of large sachets. Researchers used a specially designed laboratory system to simulate how these compounds work in the human gut. Even at the lowest dose tested (0.5 g), the GOS successfully increased beneficial gut bacteria and produced helpful compounds that support digestive health, while producing minimal gas.

Background

Prebiotics are dietary substrates selectively utilized by gut microorganisms to promote health. However, effective prebiotic doses often require inconvenient delivery formats such as sachets. This study explores whether capsule-compatible doses of galacto-oligosaccharides (GOS) can effectively modulate the gut microbiome.

Objective

To assess the impact of Bimuno® GOS at ultra-low, capsule-compatible doses (0.5, 0.75, 1.83, and 3.65 g) on the adult gut microbiome and to identify the minimal effective dose using ex vivo fermentation technology.

Results

GOS were rapidly fermented and significantly increased beneficial Bifidobacterium species even at the lowest tested dose of 0.5 g, with strong promotion of SCFA production including acetate and butyrate. GOS also enriched specific Lachnospiraceae species and Phocaeicola vulgatus, while gas production increased only mildly despite substantial SCFA increases.

Conclusion

GOS demonstrated prebiotic potential at capsule-compatible ultra-low doses, with significant microbiome modulation occurring even at 0.5 g, suggesting effective dosing at lower levels than previously expected and offering greater flexibility for nutritional product formulation and consumer convenience.
  • Published in:Metabolites,
  • Study Type:Ex vivo experimental study,
  • Source: PMID: 40863149, DOI: 10.3390/metabo15080530
Scroll to Top